GleamWall
中文EN

XRTX XORTX Therapeutics Inc. IFRS Annual reports only

Pharmaceutical Preparations · Nasdaq · SEC CIK 1729214 · Reporting currency CAD · Fiscal year ends 12/31

Financial factors as of 2021-12-31 (FY2021), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY—
TTM net income YoY-28.6%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-18.4%
ROA-13.6%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets24.0%
Debt / equity0.00x
Current ratio28.78x
Interest coverage—

Cash quality & payout

Operating cash flow / net income3.67x
Accruals ratio36.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Unit: CAD FY2021*2021-12-31FY2020*2020-12-31
Income statement
Revenue——
R&D expense853,124277,455
SG&A expense176,0999,516
Pretax income-3.65M-1.40M
Net income-1.65M-1.28M
EPS (diluted)——
Balance sheet
Cash & equivalents18.85M171,271
Receivables51,53914,351
Current assets20.17M2.06M
Total assets22.04M2.29M
Current liabilities700,9991.03M
Total liabilities5.30M1.03M
Shareholders' equity16.74M1.26M
Shares outstanding1.79M—
Cash flow statement
Operating cash flow-6.06M-728,401
Financing cash flow24.46M855,408
Depreciation & amortization17,88220,439
Stock-based compensation499,158293,443

Free plan shows the latest 2 periods; Pro shows all 3 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· This company does not report gross profit in XBRL.

· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.

· Amounts are in the company's reporting currency, CAD, not USD; the site does no currency conversion.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.